Ronald Jefferson
General Practice · Los Angeles, CANPI 1730389800
Payments from drug & device makers
Across 266 payments — averaging $169.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$41K
- Viiv Healthcare Company$2K
- Merck$566
- Johnson & Johnson$456
- AbbVie$194
- Theratechnologies Inc.$170
- plus $414 from 8 others
What the payments were for
- Speaking & faculty fees$35,98080%
- Travel & lodging$1,6654%
- Food & beverage$7,37716%
- Education$970%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 145 | $41,074 |
| Viiv Healthcare Company | 52 | $2,246 |
| Merck | 24 | $566 |
| Johnson & Johnson(2 entities) | 22 | $456 |
| AbbVie | 5 | $194 |
| Theratechnologies Inc. | 4 | $170 |
| Napo Pharmaceuticals Inc | 3 | $169 |
| EMD Serono, Inc. | 4 | $89 |
| Janssen Products, LP | 1 | $69 |
| Pfizer | 1 | $22 |
| Alkermes, Inc. | 1 | $21 |
| Dynavax Technologies Corporation | 2 | $17 |
| Melinta Therapeutics, LLC | 1 | $16 |
| Organon | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$45,120 in reported general payments places this provider in the 95th percentile of 12,963 general practice providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 345 | $1,334,501 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 95 | $443,354 |
| TivicayDolutegravir Sodium | 128 | $312,677 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 40 | $153,840 |
| DescovyEmtricitabine/Tenofov Alafenam | 64 | $137,555 |
| RukobiaFostemsavir Tromethamine | 13 | $109,698 |
| JulucaDolutegravir/Rilpivirine | 28 | $95,385 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 24 | $79,936 |
| PrezcobixDarunavir/Cobicistat | 17 | $39,540 |
| JanuviaSitagliptin Phosphate | 50 | $26,478 |
| PifeltroDoravirine | 13 | $22,437 |
| JardianceEmpagliflozin | 45 | $21,914 |
| XareltoRivaroxaban | 24 | $16,247 |
| EliquisApixaban | 21 | $13,924 |
| EntrestoSacubitril/Valsartan | 21 | $13,448 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $41,074 | $1,625,897449 claims |
| Viiv Healthcare CompanyTivicay, Rukobia, Juluca | $2,246 | $517,760169 claims |
| Janssen Products, LPSymtuza | $69 | $443,35495 claims |
| Johnson & JohnsonPrezcobix, Xarelto | $456 | $55,78641 claims |
| MerckJanuvia, Pifeltro | $566 | $48,91563 claims |
| PfizerEliquis | $22 | $13,92421 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 12,963 general practice providers in California.
Other general practice in Los Angeles
- Bruce TorkanLos Angeles$3.8M
- Abdi SameniLos Angeles$316K
- Enrique GonzalezLos Angeles$303K
- Kent HwangLos Angeles$290K
- Kyle StanleyLos Angeles$259K
- Yang ChaiLos Angeles$150K
- Richard KimLos Angeles$97K
- Hessam AazamiCanoga Park$88.4M
- Frederic MollRedwood City$5.7M
- Nathan LiLancaster$5.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.